Global Value Dossiers

Elevate Your Market Access Strategy with a Compelling Global Value Dossier

In today’s competitive healthcare landscape, demonstrating the value of your product to global stakeholders is essential. Our experts can craft comprehensive GVDs to present evidence-based messages that demonstrate what your new product brings to the market and how it will be positioned relative to other products. We organize the information so that all users are able to access the sections they need and affiliates can apply the value story to their local markets.

Key sections in a GVD include:

•    Value story
•    Disease burden
•    Unmet needs
•    Value of the product (clinical, humanistic, economic)
•    Market access strategy
•    Objection handling

Demonstrate Your Therapeutic Product's Value

Develop a Global Value Dossier that meets evolving market access and HTA expectations.

Hand interacting with digital document folders on a virtual interface, representing online file management and data organization technology

Our experts combine scientific evidence and strategic insights to help you articulate product value across global and local markets.

Download the eBook

Expert Q&A: Building Effective GVDs

Your Value Story: Key Questions to Answer

To fully understand your product’s value story, you need to take into account many different factors and perspectives. Our experts can help you answer these questions and ensure your research finding are incorporated into your GVD or other value communication materials.

Key Factors	Key Questions About Your Product
Patient Perspective	Can I afford it? Is it easy for me to adopt it?
Payer Perspective	What outcomes matter and differentiate it? Can the system afford it?
Provider Perspective	What is the best possible treatment?
Clinical Trial Results	How will the product influence the clinical pathway? Are there data that can be leveraged at launch to influence reimbursement and market access?
Economics	What are the implications versus the standard of care? How do outcomes and costs impact pricing potential? How can affirmative data (e.g., FDAMA Section 114) be generated?
Pricing & Reimbursement Landscape	How rigorously do payers manage the disease? How have payers handled reimbursement of alternative treatments?
HEOR Strategy	What additional studies will be needed to improve coverage and pricing potential?
Literature Review	What lessons from existing studies can be applied to support its value proposition?

Featured Publications

Nuabor W, Brizan J, Njue A, Upegui A. Targeted literature review of the economic and humanistic burden of invasive pneumococcal disease. Poster presented at the 14th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD); May 17, 2026. Copenhagen, Denmark.

Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S634. doi: 10.1016/j.jval.2024.10.3181

Ray KK, Catapano AL, Diamand F, Wolowacz S, Haq I, Bilitou A. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients. Poster presented at the European Society of Cardiology Congress 2022; August 26, 2022. Barcelona, Spain.

Lunan M, Hartley L, Pearson I, Doyle S. Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Poster presented at the Virtual ISPOR Europe 2021; November 3, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.